We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


New HbA1c Diabetes Diagnostic Technology from Sebia

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "New HbA1c Diabetes Diagnostic Technology from Sebia"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sebia has announced the launch of its next generation separation method for HbA1c testing.

The new test used with Sebia’s automated capillary electrophoresis product, Capillarys™ Two Flex Piercing, brings the accuracy, high throughput, and robustness required for laboratory use worldwide.

The arrival of the new method is very timely as some very significant changes have taken place. HbA1c is an important test recommended by the American Diabetic Association (ADA).

Originally used for monitoring, it has now also been recommended for diagnosis of patient glycemic status. HbA1c refers to glucose modified hemoglobin A (HbA) specifically at N-terminal valine residues of hemoglobin beta chains.

The HbA1c playing field, for both laboratories and their referral clinicians, is also changing with increased incidences of diabetes both in emerging countries, where hemoglobin disorders are prevalent, and in countries facing population migrations. HbA1c tests therefore have to detect these variants to give an accurate result.

Moreover, the International Federation of Clinical Chemistry HbA1c working group has introduced new analytical requirements and new regulations.

This group has established rules for the production of calibrators and the annual assessment of industry assays and has selected a straight and simple calculation formula.

This change of paradigm and the increased incidence of interferences caused by a patient’s clinical status, have led Sebia to develop a next generation separation method for HbA1c measurement.

Drawing on ten years’ experience in capillary electrophoresis, Sebia has adapted HbA1c technology into an assay that can be used routinely by labs around the world and also overcomes the difficulties due to the presence of blood conditions that interfere with analyses.

The high resolution capacity of capillary electrophoresis holds significant advantages over other methods. It enables pathologists to separate the HbA1c fraction from other fractions, or interfering substances, better than any other separation already existing on the market, such as HPLC, says the company.

Furthermore, unlike most competing products, Sebia’s assay uses the straight and simple calculation formula selected by the IFCC working group (HbA1c equals HbA1c/[HbA1c plus HbA0]).

The simplicity of this calculation formula leads to fewer risks from interferences and greater accuracy in the results.

The system offers a high throughput of around 40 tests per hour, without compromising the quality of separation. The product is fully compliant with international regulations and has NGSP and IFCC certification.

“Thanks to our powerful separation technology, we can now offer worldwide a product that complies with the new HbA1c requirements and responds to the unmet needs of the growing diabetes market especially for patients with a complex physiological status,” says Benoit Adelus, Sebia’s chief executive officer.

Expert users’ experience is already confirming the high quality results produced by the new system. A team at the University Hospital of Reims, France, recently demonstrated that the Sebia HbA1c assay showed no interferences or no altered results in the presence of a number of problem areas.

These include carbamylated, labile, acetylated and fetal hemoglobins, bilirubin, lipids and hemoglobin variants such as HbS, HbC, HbE and HbD. The assays showed overall excellent linearity and good reproducibility.

Further investigations are under way with key opinion leaders in different countries to explore further the unique advantages of this new test, how it contributes to the detection and monitoring of diabetes and its reliability even in physiologially complex situations.

The Sebia HbA1c assay and analyzer were also tested at a large laboratory MEDIBIO (Melun-France) under stringent conditions of use. They showed capabilities for streamlining laboratory workflow and reducing hands-on time.

“All the tests performed demonstrated the exemplary sturdiness of the equipment, which never failed despite the abusive use to which it was put,” says Dr Frank Mentz, head of the global analytical platform.